InvestorsHub Logo
Followers 0
Posts 94
Boards Moderated 0
Alias Born 05/10/2012

Re: WILD_4_IPIX post# 41929

Tuesday, 09/17/2013 11:37:29 AM

Tuesday, September 17, 2013 11:37:29 AM

Post# of 403023
Yes, I am interested. That said, I don't think there's any rush and I would like to see what Cellceutix' plans are for financing the P2b trials for ABSSSI and P2 for Oral Mucositis.

In Polymedix's Brilacidin (PMX-30063) Antibiotic Fact Sheet, published in February 2013, it was stated "Based on the successful results of this trial, which suggests that shorter courses of therapy and lower doses could be effective, a dose-optimization Phase 2B study is planned. The Phase 2B will study lower doses and shorter courses of therapy." Brilacidin (PMX-30063) Antibiotic Fact Sheet
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News